PureTech Health plc PRTCY
17.29 USD +0.93 (+5.68%)
At closeNov 4, 2026, 4:00 PM EST
16.01 Day range 16.01
13.93 52-week range 19.92
- YTD
- +3.91%
- 1 year
- +1.11%
- Market cap
- 423.92M
- YTD return
- +3.91%
- 1-year return
- +1.11%
- Volume
- 1
- Avg volume
- 2.37K
- Open
- 16.01
- Previous close
- 16.36
- Day's range
- 16.01 – 16.01
- 52-week range
- 13.93 – 19.92
15m +1.98 (+12.93%)
Financials — quick view
PRTCY Revenue — annual 4.66M
PRTCY Net income — annual -109.74M
PRTCY EPS — annual -4.60
News
PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category 
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 
PureTech Health plc (PRTCY) Q2 2026 Earnings Call Transcript 
PureTech Health H1 Earnings Call Highlights 
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) 
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
Your note
Sign in to keep a note on PRTCY — it syncs with the Stock Master app.